Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, randomized, double-blind, placebo-controlled,
single-ascending dose (SAD) phase 1 study to evaluate the safety and tolerability of
single-ascending doses of BAR 502 in healthy male and female subjects.